Galmed Targets Cancer and Heart Disease
Company Announcements

Galmed Targets Cancer and Heart Disease

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals is broadening its horizons by expanding its drug development activities into cancer and cardiometabolic diseases, leveraging its advanced SCD1 inhibitor Aramchol, previously focused on liver disease. The company plans to explore Aramchol-based drug combinations to enhance oncology treatments and target cardiac fibrosis, with new study data expected by the end of 2024. This strategic move is spurred by recent scientific insights and an increase in funds, promising to address significant health issues affecting millions globally.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGalmed Pharmaceuticals Amends Equity Purchase Agreement
TheFlyGalmed files to sell 1M shares of common stock for holders
TipRanks Auto-Generated NewsdeskGalmed Reports Breakthrough in MASH Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App